長生生物7月24日(ri)(ri)(ri)晚(wan)發布關于公(gong)司(si)股(gu)票(piao)(piao)交易實施(shi)其(qi)他(ta)風險警示(shi)暨子公(gong)司(si)停產(chan)的公(gong)告(gao)。公(gong)司(si)7月25日(ri)(ri)(ri)開市起(qi)停牌(pai)一天,7月26日(ri)(ri)(ri)開市起(qi)被(bei)實施(shi)其(qi)他(ta)風險警示(shi),公(gong)司(si)股(gu)票(piao)(piao)簡稱由(you)“長生生物”變更為“ST長生”,公(gong)司(si)股(gu)票(piao)(piao)交易日(ri)(ri)(ri)漲跌幅(fu)限(xian)制為5%。
公司全面停產
公告顯(xian)示,7月(yue)15日,國家藥品監督管理(li)局網站披(pi)露了《關于長春長生(sheng)(sheng)生(sheng)(sheng)物科(ke)技有限責任(ren)公司違法違規生(sheng)(sheng)產凍干人用狂犬(quan)病疫(yi)苗的通告》,7月(yue)18日,公司全資子(zi)公司長春長生(sheng)(sheng)收(shou)到《吉林省食品藥品監督管理(li)局行政(zheng)處罰決定書》。
近日(ri),吉林(lin)省(sheng)食品(pin)藥品(pin)監督管理局(ju)已收(shou)回(hui)長(chang)春(chun)長(chang)生狂犬(quan)病疫苗(miao)藥品(pin)GMP證書。目前長(chang)春(chun)長(chang)生停(ting)(ting)止(zhi)狂犬(quan)病疫苗(miao)生產(chan)及銷售。子公(gong)(gong)(gong)司所有產(chan)品(pin)已被(bei)暫(zan)停(ting)(ting)批(pi)簽發。目前除百(bai)白破聯合疫苗(miao)、凍干人用狂犬(quan)病疫苗(miao)產(chan)品(pin)被(bei)責令停(ting)(ting)產(chan)外,公(gong)(gong)(gong)司經研究決定對公(gong)(gong)(gong)司其他(ta)產(chan)品(pin)也采取全(quan)面(mian)自主停(ting)(ting)產(chan),以上生產(chan)車(che)間在停(ting)(ting)產(chan)期間自查自糾,進行全(quan)面(mian)、徹(che)底的整改(gai)。目前復(fu)產(chan)時間不(bu)確(que)定。公(gong)(gong)(gong)司生產(chan)經營活動受到嚴重(zhong)影響且預計在三(san)個月(yue)內不(bu)能(neng)恢復(fu)正常,根(gen)據《深圳證券交易所股票(piao)上市規則》13.3.1條規定,公(gong)(gong)(gong)司股票(piao)自復(fu)牌(pai)之日(ri)起將實施其他(ta)風(feng)險警示。
7月23日下(xia)午15時,長(chang)(chang)(chang)(chang)春市長(chang)(chang)(chang)(chang)春新區(qu)公(gong)安(an)分局(ju)依(yi)據吉(ji)林(lin)省食品藥品監督(du)管理局(ju)《涉嫌(xian)犯罪案件移送(song)書》,對長(chang)(chang)(chang)(chang)春長(chang)(chang)(chang)(chang)生(sheng)生(sheng)產凍干人用狂犬病疫苗涉嫌(xian)違(wei)法犯罪案件立案調查,將(jiang)主要涉案人員(yuan)公(gong)司(si)(si)董事長(chang)(chang)(chang)(chang)、3名公(gong)司(si)(si)高(gao)管和2名中(zhong)層(ceng)人員(yuan)帶(dai)至公(gong)安(an)機關依(yi)法審查。公(gong)司(si)(si)已經(jing)披露了《關于(yu)董事長(chang)(chang)(chang)(chang)及部分高(gao)管無法正常履職的公(gong)告(gao)》。以上被公(gong)安(an)機關帶(dai)走的六人中(zhong)有兩名公(gong)司(si)(si)董事。
嚴重影響下半年業績
長(chang)生(sheng)(sheng)生(sheng)(sheng)物表示(shi),隨著狂犬(quan)疫(yi)苗(miao)事件的(de)(de)持續發酵,導致長(chang)春長(chang)生(sheng)(sheng)其他產(chan)(chan)品生(sheng)(sheng)產(chan)(chan)和銷售受到重(zhong)大影(ying)(ying)響,目前(qian)公(gong)司(si)(si)所有產(chan)(chan)品批(pi)簽發暫停,公(gong)司(si)(si)將(jiang)(jiang)(jiang)組織自查隊(dui)伍進行自查自糾,進行全面(mian)、徹(che)底(di)的(de)(de)整改。目前(qian)復產(chan)(chan)時間尚不確(que)定。本次事件將(jiang)(jiang)(jiang)會對(dui)公(gong)司(si)(si)2018年下半年業績產(chan)(chan)生(sheng)(sheng)重(zhong)大負面(mian)影(ying)(ying)響,同(tong)時由于本次違規事項,預計對(dui)未來公(gong)司(si)(si)疫(yi)苗(miao)銷售將(jiang)(jiang)(jiang)存在(zai)一定的(de)(de)阻礙(ai),對(dui)未來經(jing)營業績也將(jiang)(jiang)(jiang)產(chan)(chan)生(sheng)(sheng)重(zhong)大影(ying)(ying)響,影(ying)(ying)響程度尚不確(que)定。
受疫苗事件影(ying)響,近日(ri)多家基金公(gong)司下調(diao)長生生物估(gu)值。招(zhao)商基金、博時基金和易方達(da)調(diao)整(zheng)后的(de)長生生物估(gu)值價(jia)格為7.71元/股(gu)。
長生(sheng)(sheng)生(sheng)(sheng)物大(da)(da)股東、董監(jian)(jian)高(gao)被實施限售(shou)也影響到其(qi)股權質押(ya)機構興業(ye)證券的表(biao)現。興業(ye)證券24日發(fa)布(bu)公(gong)告稱,虞臣潘、張洺豪分別質押(ya)長生(sheng)(sheng)生(sheng)(sheng)物0.11億股和1.67億股,待購回金額6.75億元;鑒于長生(sheng)(sheng)生(sheng)(sheng)物已被國家(jia)藥監(jian)(jian)局、證監(jian)(jian)會(hui)立案調查(cha),深交所(suo)對長生(sheng)(sheng)生(sheng)(sheng)物大(da)(da)股東、董監(jian)(jian)高(gao)所(suo)持股份實施限售(shou),公(gong)司(si)(si)將實時跟蹤事(shi)態發(fa)展,及時評估對公(gong)司(si)(si)經營狀況的影響并作出應對。
此前(qian),長生(sheng)(sheng)生(sheng)(sheng)物(wu)公(gong)告稱,公(gong)司(si)控(kong)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)東張洺(ming)豪(hao)將其(qi)(qi)持(chi)有的7336.24萬股(gu)(gu)(gu)(gu)(gu)(gu)(gu)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)份進行補充質押(ya),質權人(ren)為(wei)(wei)(wei)興(xing)業證券。公(gong)開資料顯(xian)示,張洺(ming)豪(hao)是長生(sheng)(sheng)生(sheng)(sheng)物(wu)實控(kong)人(ren)高(gao)俊芳(fang)之子,與(yu)高(gao)俊芳(fang)、張友(you)奎(高(gao)俊芳(fang)丈夫)為(wei)(wei)(wei)公(gong)司(si)一致行動人(ren),截至(zhi)公(gong)告披(pi)露日(ri),三人(ren)合計持(chi)有公(gong)司(si)近(jin)3.57億(yi)股(gu)(gu)(gu)(gu)(gu)(gu)(gu),占公(gong)司(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)的36.66%。其(qi)(qi)中,張洺(ming)豪(hao)持(chi)有長生(sheng)(sheng)生(sheng)(sheng)物(wu)約1.74億(yi)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)份,累計質押(ya)近(jin)1.67億(yi)股(gu)(gu)(gu)(gu)(gu)(gu)(gu),占公(gong)司(si)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)本(ben)比17.14%,占其(qi)(qi)持(chi)股(gu)(gu)(gu)(gu)(gu)(gu)(gu)比例為(wei)(wei)(wei)95.86%。
中(zhong)(zhong)證(zheng)(zheng)(zheng)網(wang)(wang)聲(sheng)明:凡本網(wang)(wang)注明“來(lai)源(yuan):中(zhong)(zhong)國(guo)證(zheng)(zheng)(zheng)券報·中(zhong)(zhong)證(zheng)(zheng)(zheng)網(wang)(wang)”的(de)所有作品(pin),版權均(jun)屬于(yu)中(zhong)(zhong)國(guo)證(zheng)(zheng)(zheng)券報、中(zhong)(zhong)證(zheng)(zheng)(zheng)網(wang)(wang)。中(zhong)(zhong)國(guo)證(zheng)(zheng)(zheng)券報·中(zhong)(zhong)證(zheng)(zheng)(zheng)網(wang)(wang)與作品(pin)作者(zhe)(zhe)聯(lian)合聲(sheng)明,任何組織未(wei)經中(zhong)(zhong)國(guo)證(zheng)(zheng)(zheng)券報、中(zhong)(zhong)證(zheng)(zheng)(zheng)網(wang)(wang)以及(ji)作者(zhe)(zhe)書面授權不得轉(zhuan)載(zai)、摘(zhai)編或(huo)利用(yong)其(qi)(qi)(qi)它方(fang)式使用(yong)上(shang)述(shu)作品(pin)。凡本網(wang)(wang)注明來(lai)源(yuan)非(fei)中(zhong)(zhong)國(guo)證(zheng)(zheng)(zheng)券報·中(zhong)(zhong)證(zheng)(zheng)(zheng)網(wang)(wang)的(de)作品(pin),均(jun)轉(zhuan)載(zai)自其(qi)(qi)(qi)它媒體,轉(zhuan)載(zai)目的(de)在(zai)于(yu)更好(hao)服(fu)務讀(du)者(zhe)(zhe)、傳遞信(xin)息之(zhi)需(xu),并(bing)不代表本網(wang)(wang)贊同其(qi)(qi)(qi)觀點,本網(wang)(wang)亦(yi)不對其(qi)(qi)(qi)真實性負責,持(chi)異議者(zhe)(zhe)應與原出處(chu)單位(wei)主(zhu)張權利。
特別鏈接:政府部門交易機構證券期貨四所兩司新聞發布平臺友情鏈接版權聲明
關于報社關于本站廣告發布免責條款
中國證券報社版權所有,未經書面授權不得復制或建立鏡像 經營許可證編號:京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved
中國證券報社版權(quan)所(suo)有,未經書面授權(quan)不得復制或建立鏡像
經(jing)營許可證編號:京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved